0JW9.L

Lite Strategy, Inc. is a pharmaceutical company currently in the clinical development phase, primarily dedicated to creating novel treatments for various forms of cancer. Among its key initiatives, the company is advancing ME-344, an intravenously administered small molecule. This therapy is designed to inhibit mitochondrial oxidative phosphorylation and aims to combat specific cancer types, including human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and other solid tumors. In addition to its drug development activities, Lite Strategy also engages in the management of digital asset treasuries. The organization, which was formerly known as MEI Pharma, Inc., is slated to officially adopt the name Lite Strategy, Inc. in September 2025. Established in 2000, the company maintains its headquarters in San Diego, California.